{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:46:32Z","timestamp":1792194392219,"version":"4.4.0"},"reference-count":156,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastrointestinal Endoscopy Clinics of North America"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.giec.2025.05.004","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T03:59:31Z","timestamp":1753156771000},"page":"171-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chemoprevention in Barrett\u2019s Esophagus: An Updated Review"],"prefix":"10.1016","volume":"36","author":[{"given":"Sunil","family":"Samnani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz A.","family":"Jankowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Moayyedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.giec.2025.05.004_bib2","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1038\/s41598-018-19819-8","article-title":"Global Incidence and mortality of oesophageal cancer and their correlation with socioeconomic indicators temporal patterns and trends in 41 countries","volume":"8","author":"Wong","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.giec.2025.05.004_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cgh.2006.09.016","article-title":"Time trends of gastroesophageal reflux disease: a systematic review","volume":"5","author":"El-Serag","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.giec.2025.05.004_bib4","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/gut.2004.063685","article-title":"Increasing incidence of Barrett's oesophagus in the general population","volume":"54","author":"van Soest","year":"2005","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.giec.2025.05.004_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41572-019-0086-z","article-title":"Barrett oesophagus","volume":"5","author":"Peters","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.giec.2025.05.004_bib6","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0002-9440(10)65346-1","article-title":"Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus","volume":"154","author":"Jankowski","year":"1999","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1016\/j.giec.2025.05.004_bib7","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/ng.2408","article-title":"Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus","volume":"44","author":"Su","year":"2012","journal-title":"Nat Genet"},{"issue":"30","key":"10.1016\/j.giec.2025.05.004_bib8","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.3748\/wjg.v16.i30.3762","article-title":"Pathophysiology and treatment of Barrett's esophagus","volume":"16","author":"Oh","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.giec.2025.05.004_bib9","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/gutjnl-2014-308802","article-title":"Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression","volume":"65","author":"Kastelein","year":"2016","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.giec.2025.05.004_bib10","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ueg2.12114","article-title":"Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression","volume":"9","author":"Klaver","year":"2021","journal-title":"United European Gastroenterol J"},{"issue":"1","key":"10.1016\/j.giec.2025.05.004_bib11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/ajg.2015.322","article-title":"ACG clinical guideline: diagnosis and management of Barrett's esophagus","volume":"111","author":"Shaheen","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.giec.2025.05.004_bib12","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.gie.2017.10.011","article-title":"Endoscopic eradication therapy for patients with Barrett's esophagus-associated dysplasia and intramucosal cancer","volume":"87","author":"Wani","year":"2018","journal-title":"Gastrointest Endosc"},{"issue":"5","key":"10.1016\/j.giec.2025.05.004_bib13","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/ajg.2015.55","article-title":"BOB CAT: a large-scale review and Delphi consensus for management of Barrett's esophagus with no dysplasia, indefinite for, or low-grade dysplasia","volume":"110","author":"Bennett","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.giec.2025.05.004_bib14","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/ajg.2014.156","article-title":"Surveillance of Barrett's esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study","volume":"109","author":"Verbeek","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.giec.2025.05.004_bib15","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/gast.2002.31879","article-title":"Surveillance and survival in Barrett's adenocarcinomas: a population-based study","volume":"122","author":"Corley","year":"2002","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.giec.2025.05.004_bib16","article-title":"Incidence of esophageal cancer in the United States from 2001-2015: a United States cancer statistics analysis of 50 states","volume":"10","author":"Patel","year":"2018","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.giec.2025.05.004_bib17","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/aje\/kwi218","article-title":"Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus","volume":"162","author":"Ford","year":"2005","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.giec.2025.05.004_bib18","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.gie.2019.05.030","article-title":"Systematic review and meta-analysis of prevalence and risk factors for Barrett's esophagus","volume":"90","author":"Qumseya","year":"2019","journal-title":"Gastrointest Endosc"},{"issue":"11","key":"10.1016\/j.giec.2025.05.004_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju252","article-title":"Obesity and risk of esophageal adenocarcinoma and Barrett's esophagus: a Mendelian randomization study","volume":"106","author":"Thrift","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.giec.2025.05.004_bib20","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2017.07.046","article-title":"The epidemiology of esophageal adenocarcinoma","volume":"154","author":"Coleman","year":"2018","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.giec.2025.05.004_bib21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.gastro.2011.10.034","article-title":"Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett's esophagus","volume":"142","author":"Coleman","year":"2012","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.giec.2025.05.004_bib22","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s41395-018-0070-3","article-title":"Helicobacter pylori infection is associated with reduced risk of Barrett's esophagus: an analysis of the Barrett's and esophageal adenocarcinoma consortium","volume":"113","author":"Wang","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.giec.2025.05.004_bib23","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.3945\/jn.110.124362","article-title":"Dietary antioxidant and mineral intake in humans is associated with reduced risk of esophageal adenocarcinoma but not reflux esophagitis or Barrett's esophagus","volume":"140","author":"Murphy","year":"2010","journal-title":"J Nutr"},{"issue":"3","key":"10.1016\/j.giec.2025.05.004_bib24","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.gastro.2024.03.016","article-title":"Risk of esophageal adenocarcinoma after helicobacter pylori eradication treatment in a population-based multinational cohort study","volume":"167","author":"Wiklund","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.giec.2025.05.004_bib25","series-title":"Gastrointestinal oncology: a critical multidisciplinary team approach","author":"Jankowski","year":"2024"},{"issue":"2","key":"10.1016\/j.giec.2025.05.004_bib26","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1053\/j.gastro.2012.04.032","article-title":"Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process","volume":"143","author":"Bennett","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.giec.2025.05.004_bib27","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.gastro.2011.04.061","article-title":"Durability of radiofrequency ablation in Barrett's esophagus with dysplasia","volume":"141","author":"Shaheen","year":"2011","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1016\/j.giec.2025.05.004_bib28","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1056\/NEJMoa1103042","article-title":"Incidence of adenocarcinoma among patients with Barrett's esophagus","volume":"365","author":"Hvid-Jensen","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.giec.2025.05.004_bib29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/gast.2002.30297","article-title":"Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review","volume":"122","author":"Dulai","year":"2002","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.giec.2025.05.004_bib30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ncpgasthep0412","article-title":"A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer","volume":"3","author":"Jankowski","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.giec.2025.05.004_bib31","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11894-023-00905-5","article-title":"Revisiting proton pump inhibitors as chemoprophylaxis against the progression of Barrett's esophagus","volume":"25","author":"Shah","year":"2023","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.giec.2025.05.004_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211033730","article-title":"Chemoprevention in Barrett's esophagus and esophageal adenocarcinoma","volume":"14","author":"Alkhayyat","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"issue":"8","key":"10.1016\/j.giec.2025.05.004_bib33","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s10620-018-5149-6","article-title":"Chemoprevention of Barrett's esophagus and esophageal adenocarcinoma","volume":"63","author":"Bresalier","year":"2018","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.giec.2025.05.004_bib34","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/gutjnl-2020-321365","article-title":"Global prevalence of Barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis","volume":"70","author":"Eusebi","year":"2021","journal-title":"Gut"},{"issue":"28","key":"10.1016\/j.giec.2025.05.004_bib35","doi-asserted-by":"crossref","first-page":"9611","DOI":"10.3748\/wjg.v20.i28.9611","article-title":"Lifetime risk of esophageal adenocarcinoma in patients with Barrett's esophagus","volume":"20","author":"Gatenby","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"8","key":"10.1016\/j.giec.2025.05.004_bib36","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/gut.2009.176701","article-title":"Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study","volume":"59","author":"de Jonge","year":"2010","journal-title":"Gut"},{"issue":"13","key":"10.1016\/j.giec.2025.05.004_bib37","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/jnci\/djr203","article-title":"Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study","volume":"103","author":"Bhat","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.giec.2025.05.004_bib38","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1053\/j.gastro.2013.02.050","article-title":"Cause-specific mortality of people with Barrett's esophagus compared with the general population: a population-based cohort study","volume":"144","author":"Solaymani-Dodaran","year":"2013","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.giec.2025.05.004_bib39","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1016\/j.cgh.2022.06.003","article-title":"AGA clinical practice update on new technology and innovation for surveillance and screening in Barrett's esophagus: expert review","volume":"20","author":"Muthusamy","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.giec.2025.05.004_bib40","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1055\/a-2176-2440","article-title":"Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) guideline","volume":"55","author":"Weusten","year":"2023","journal-title":"Endoscopy"},{"issue":"1","key":"10.1016\/j.giec.2025.05.004_bib41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/gutjnl-2013-305372","article-title":"British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus","volume":"63","author":"Fitzgerald","year":"2014","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.giec.2025.05.004_bib42","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.gastro.2024.04.030","article-title":"Targeted screening for Barrett's esophagus and esophageal cancer: post hoc analysis from the randomized BEST3 trial","volume":"167","author":"Tan","year":"2024","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.giec.2025.05.004_bib43","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.giec.2020.08.008","article-title":"Current status of chemoprevention in Barrett's esophagus","volume":"31","author":"Moayyedi","year":"2021","journal-title":"Gastrointest Endosc Clin N Am"},{"issue":"11","key":"10.1016\/j.giec.2025.05.004_bib44","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41568-021-00400-x","article-title":"Evolution and progression of Barrett's oesophagus to oesophageal cancer","volume":"21","author":"Killcoyne","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.giec.2025.05.004_bib45","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/cam4.4447","article-title":"Barrett's esophagus: the pathomorphological and molecular genetic keystones of neoplastic progression","volume":"11","author":"Maslyonkina","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.giec.2025.05.004_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fgstr.2023.1007456","article-title":"Molecular biomarkers of progression from Barrett\u2019s esophagus to esophageal adenocarcinoma. Original Research","volume":"2","author":"Taylor","year":"2023","journal-title":"Front Gastroenterol"},{"key":"10.1016\/j.giec.2025.05.004_bib47","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/B978-0-12-381280-3.00010-5","article-title":"Cdx genes, inflammation, and the pathogenesis of intestinal metaplasia","volume":"96","author":"Stairs","year":"2010","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"2","key":"10.1016\/j.giec.2025.05.004_bib48","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.gtc.2015.02.010","article-title":"The effect of proton pump inhibitors on Barrett's esophagus","volume":"44","author":"Dunbar","year":"2015","journal-title":"Gastroenterol Clin North Am"},{"issue":"9","key":"10.1016\/j.giec.2025.05.004_bib49","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1172\/JCI119018","article-title":"Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model","volume":"98","author":"Fitzgerald","year":"1996","journal-title":"J Clin Investig"},{"issue":"23","key":"10.1016\/j.giec.2025.05.004_bib50","doi-asserted-by":"crossref","first-page":"9083","DOI":"10.1158\/0008-5472.CAN-09-2518","article-title":"In benign Barrett's epithelial cells, acid exposure generates reactive oxygen species that cause DNA double-strand breaks","volume":"69","author":"Zhang","year":"2009","journal-title":"Cancer Res"},{"issue":"55","key":"10.1016\/j.giec.2025.05.004_bib51","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1038\/sj.onc.1204947","article-title":"Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus","volume":"20","author":"Umansky","year":"2001","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.giec.2025.05.004_bib52","article-title":"Effect of proton pump inhibitor therapy on NOX5, mPGES1 and iNOS expression in Barrett's esophagus","volume":"9","author":"Li","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.giec.2025.05.004_bib53","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1053\/gast.2002.30993","article-title":"Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus","volume":"122","author":"Souza","year":"2002","journal-title":"Gastroenterology"},{"issue":"14","key":"10.1016\/j.giec.2025.05.004_bib54","first-page":"2929","article-title":"Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas","volume":"58","author":"Wilson","year":"1998","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.giec.2025.05.004_bib55","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1136\/gut.2007.121244","article-title":"COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma","volume":"56","author":"Song","year":"2007","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.giec.2025.05.004_bib56","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/j.gastro.2012.06.044","article-title":"A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus","volume":"143","author":"Falk","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.giec.2025.05.004_bib57","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1053\/gast.1999.0029900327","article-title":"Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression","volume":"117","author":"Ouatu-Lascar","year":"1999","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.giec.2025.05.004_bib58","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1053\/gast.2003.50091","article-title":"Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor","volume":"124","author":"Haigh","year":"2003","journal-title":"Gastroenterology"},{"issue":"45","key":"10.1016\/j.giec.2025.05.004_bib59","doi-asserted-by":"crossref","first-page":"6560","DOI":"10.3748\/wjg.v18.i45.6560","article-title":"Role of gastrin-peptides in Barrett's and colorectal carcinogenesis","volume":"18","author":"Chueca","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.giec.2025.05.004_bib60","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/gut.2009.186775","article-title":"Long-term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett's oesophagus in vivo","volume":"59","author":"Obszynska","year":"2010","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.giec.2025.05.004_bib61","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/ajg.2009.629","article-title":"Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus","volume":"105","author":"Wang","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"10145","key":"10.1016\/j.giec.2025.05.004_bib62","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0140-6736(18)31388-6","article-title":"Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial","volume":"392","author":"Jankowski","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.giec.2025.05.004_bib63","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.cgh.2009.06.001","article-title":"Medication usage and the risk of neoplasia in patients with Barrett's esophagus","volume":"7","author":"Nguyen","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.giec.2025.05.004_bib64","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/j.1572-0241.2004.30228.x","article-title":"Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus","volume":"99","author":"El-Serag","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.giec.2025.05.004_bib65","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1136\/gut.2005.086579","article-title":"Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK","volume":"55","author":"Garc\u00eda Rodr\u00edguez","year":"2006","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.giec.2025.05.004_bib66","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1136\/gutjnl-2013-305997","article-title":"Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis","volume":"63","author":"Singh","year":"2014","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.giec.2025.05.004_bib67","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1007\/s00432-021-03544-3","article-title":"Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis","volume":"147","author":"Chen","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.giec.2025.05.004_bib68","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/17512433.2022.2008909","article-title":"Proton pump inhibitors may reduce the risk of high-grade dysplasia and\/or esophageal adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis","volume":"15","author":"Yao","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.giec.2025.05.004_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169691","article-title":"Proton pump inhibitors do not reduce the risk of esophageal adenocarcinoma in patients with barrett's esophagus: a systematic review and meta-analysis","volume":"12","author":"Hu","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.giec.2025.05.004_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2023.100692","article-title":"Assessment of the relationship between gastric-acid suppressants and the risk of esophageal adenocarcinoma: a systematic review and meta-analysis","volume":"98","author":"Kasiri","year":"2023","journal-title":"Curr Ther Res Clin Exp"},{"issue":"3","key":"10.1016\/j.giec.2025.05.004_bib71","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1442-2050.2003.00327.x","article-title":"Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett's esophagus","volume":"16","author":"Yeh","year":"2003","journal-title":"Dis Esophagus"},{"issue":"7","key":"10.1016\/j.giec.2025.05.004_bib72","first-page":"989","article-title":"Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus","volume":"89","author":"Katzka","year":"1994","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.giec.2025.05.004_bib73","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1365-2036.2004.02127.x","article-title":"Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors","volume":"20","author":"Gerson","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.giec.2025.05.004_bib74","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/00042737-200211000-00005","article-title":"Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy","volume":"14","author":"Basu","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.giec.2025.05.004_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfma.2025.03.006","article-title":"Comparison of continuous versus on-demand proton pump inhibitor therapy in symptom control of patients with Barrett's esophagus","author":"Kao","year":"2025","journal-title":"J Formos Med Assoc"},{"issue":"12","key":"10.1016\/j.giec.2025.05.004_bib76","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/MEG.0000000000001198","article-title":"Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis","volume":"30","author":"Islam","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.giec.2025.05.004_bib77","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d2690","article-title":"Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study","volume":"342","author":"Charlot","year":"2011","journal-title":"BMJ"},{"issue":"23","key":"10.1016\/j.giec.2025.05.004_bib78","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1001\/jama.294.23.2989","article-title":"Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease","volume":"294","author":"Dial","year":"2005","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.giec.2025.05.004_bib79","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","article-title":"Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis","volume":"73","author":"Gomm","year":"2016","journal-title":"JAMA Neurol"},{"issue":"16","key":"10.1016\/j.giec.2025.05.004_bib80","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1001\/jama.292.16.1955","article-title":"Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs","volume":"292","author":"Laheij","year":"2004","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.giec.2025.05.004_bib81","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","article-title":"Proton pump inhibitor use and the risk of chronic kidney disease","volume":"176","author":"Lazarus","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"9","key":"10.1016\/j.giec.2025.05.004_bib82","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/j.1572-0241.2007.01275.x","article-title":"Systematic review of the risk of enteric infection in patients taking acid suppression","volume":"102","author":"Leonard","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.giec.2025.05.004_bib83","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","article-title":"Complications of proton pump inhibitor therapy","volume":"153","author":"Vaezi","year":"2017","journal-title":"Gastroenterology"},{"issue":"24","key":"10.1016\/j.giec.2025.05.004_bib84","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.giec.2025.05.004_bib85","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015735","article-title":"Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans","volume":"7","author":"Xie","year":"2017","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.giec.2025.05.004_bib86","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.giec.2025.05.004_bib87","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/apt.13194","article-title":"Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies","volume":"41","author":"Attwood","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.giec.2025.05.004_bib88","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease","volume":"117","author":"Katz","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.giec.2025.05.004_bib89","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2021.12.247","article-title":"AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review","volume":"162","author":"Targownik","year":"2022","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.giec.2025.05.004_bib90","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.14309\/ajg.0000000000001788","article-title":"Guideline to practice: diagnosis and management of Barrett's esophagus: an updated ACG guideline","volume":"117","author":"Shaheen","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.giec.2025.05.004_bib91","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241251567","article-title":"Potassium-competitive acid blockers and proton-pump inhibitors for healing of erosive esophagitis: a systematic review and network meta-analysis","volume":"17","author":"Liu","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"issue":"6","key":"10.1016\/j.giec.2025.05.004_bib92","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/jgh.16486","article-title":"Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: a systematic review with meta-analysis of randomized controlled trials","volume":"39","author":"Simadibrata","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"issue":"47","key":"10.1016\/j.giec.2025.05.004_bib93","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000031807","article-title":"Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: a PRISMA-compliant systematic review and network meta-analysis","volume":"101","author":"Yang","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"10.1016\/j.giec.2025.05.004_bib94","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/MCG.0000000000002052","article-title":"Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors in treating erosive esophagitis: a meta-analysis based on randomized controlled trials","volume":"58","author":"Fang","year":"2024","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.giec.2025.05.004_bib95","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/j.gastro.2022.09.041","article-title":"Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial","volume":"164","author":"Laine","year":"2023","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.giec.2025.05.004_bib96","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1053\/j.gastro.2024.06.038","article-title":"AGA clinical practice update on integrating potassium-competitive acid blockers into clinical practice: expert review","volume":"167","author":"Patel","year":"2024","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.giec.2025.05.004_bib97","first-page":"990","article-title":"Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence","volume":"96","author":"Morris","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.giec.2025.05.004_bib98","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/annonc\/mdu225","article-title":"Estimates of benefits and harms of prophylactic use of aspirin in the general population","volume":"26","author":"Cuzick","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.giec.2025.05.004_bib99","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrc780","article-title":"NF-kappaB in cancer: from innocent bystander to major culprit","volume":"2","author":"Karin","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.giec.2025.05.004_bib100","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1095\/biolreprod66.6.1667","article-title":"Nuclear factor kappa B activation and regulation of cyclooxygenase type-2 expression in human amnion mesenchymal cells by interleukin-1beta","volume":"66","author":"Yan","year":"2002","journal-title":"Biol Reprod"},{"issue":"2","key":"10.1016\/j.giec.2025.05.004_bib101","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/156800912799095199","article-title":"Characterization of the prostaglandin E2 pathway in a rat model of esophageal adenocarcinoma","volume":"12","author":"Piazuelo","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"issue":"6","key":"10.1016\/j.giec.2025.05.004_bib102","doi-asserted-by":"crossref","first-page":"G991","DOI":"10.1152\/ajpgi.00215.2005","article-title":"Acid increases MAPK-mediated proliferation in Barrett's esophageal adenocarcinoma cells via intracellular acidification through a Cl-\/HCO3- exchanger","volume":"289","author":"Sarosi","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"4","key":"10.1016\/j.giec.2025.05.004_bib103","first-page":"606","article-title":"Aspirin prevents NF-\u03baB activation and CDX2 expression stimulated by acid and bile salts in oesophageal squamous cells of patients with Barrett's oesophagus","volume":"67","author":"Huo","year":"2018","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.giec.2025.05.004_bib104","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ccr.2010.04.023","article-title":"NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling","volume":"17","author":"Zhou","year":"2010","journal-title":"Cancer Cell"},{"issue":"39","key":"10.1016\/j.giec.2025.05.004_bib105","doi-asserted-by":"crossref","first-page":"8021","DOI":"10.1038\/sj.onc.1206837","article-title":"Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition","volume":"22","author":"Totzke","year":"2003","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.giec.2025.05.004_bib106","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00262-007-0374-4","article-title":"Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells","volume":"57","author":"Ryan","year":"2008","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"10.1016\/j.giec.2025.05.004_bib107","article-title":"Aspirin use is associated with lower risk of Barrett's esophagus in women","volume":"8","author":"Jovani","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"2","key":"10.1016\/j.giec.2025.05.004_bib108","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10620-014-3349-2","article-title":"Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagus","volume":"60","author":"Schneider","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"9","key":"10.1016\/j.giec.2025.05.004_bib109","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1038\/bjc.2014.127","article-title":"Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis","volume":"110","author":"Zhang","year":"2014","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.giec.2025.05.004_bib110","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/ajg.2016.348","article-title":"Nonsteroidal anti-inflammatory drug use is not associated with reduced risk of Barrett's esophagus","volume":"111","author":"Thrift","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.giec.2025.05.004_bib111","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1053\/j.gastro.2011.11.019","article-title":"Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis","volume":"142","author":"Liao","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.giec.2025.05.004_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2020.101808","article-title":"Use of metformin and aspirin is associated with delayed cancer incidence","volume":"69","author":"Sung","year":"2020","journal-title":"Cancer Epidemiol"},{"issue":"7","key":"10.1016\/j.giec.2025.05.004_bib113","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/jnci\/djk112","article-title":"Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial","volume":"99","author":"Heath","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"10.1016\/j.giec.2025.05.004_bib114","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.giec.2025.05.004_bib115","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S2468-1253(18)30037-2","article-title":"Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials","volume":"3","author":"Scally","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.giec.2025.05.004_bib116","doi-asserted-by":"crossref","first-page":"143","DOI":"10.14336\/AD.2017.0306","article-title":"A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly","volume":"9","author":"Wongrakpanich","year":"2018","journal-title":"Aging Dis"},{"issue":"9894","key":"10.1016\/j.giec.2025.05.004_bib117","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Bhala","year":"2013","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.giec.2025.05.004_bib118","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4292\/wjgpt.v4.i3.69","article-title":"Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition","volume":"4","author":"Beales","year":"2013","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.giec.2025.05.004_bib119","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s12029-017-9983-0","article-title":"Systematic review and meta-analysis: use of statins is associated with a reduced incidence of oesophageal adenocarcinoma","volume":"49","author":"Thomas","year":"2018","journal-title":"J Gastrointest Cancer"},{"issue":"5","key":"10.1016\/j.giec.2025.05.004_bib120","doi-asserted-by":"crossref","first-page":"692","DOI":"10.21037\/tlcr.2019.09.08","article-title":"Current perspectives on statins as potential anti-cancer therapeutics: clinical outcomes and underlying molecular mechanisms","volume":"8","author":"Fatehi Hassanabad","year":"2019","journal-title":"Transl Lung Cancer Res"},{"issue":"6","key":"10.1016\/j.giec.2025.05.004_bib121","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1053\/j.gastro.2015.07.009","article-title":"Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study","volume":"149","author":"Nguyen","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.giec.2025.05.004_bib122","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1158\/1940-6207.CAPR-20-0274","article-title":"Association of Common use pharmaceuticals in reducing risk of esophageal adenocarcinoma: a SEER-medicare analysis","volume":"14","author":"Loomans-Kropp","year":"2021","journal-title":"Cancer Prev Res (Phila)"},{"issue":"3","key":"10.1016\/j.giec.2025.05.004_bib123","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1053\/j.gastro.2013.11.046","article-title":"Statin use is associated with reduced risk of histologic subtypes of esophageal cancer: a nested case-control analysis","volume":"146","author":"Alexandre","year":"2014","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.giec.2025.05.004_bib124","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.cgh.2012.12.036","article-title":"Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis","volume":"11","author":"Singh","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.giec.2025.05.004_bib125","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/ijc.28869","article-title":"Hormone replacement therapy and oral contraceptives and risk of oesophageal adenocarcinoma: a systematic review and meta-analysis","volume":"135","author":"Lagergren","year":"2014","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.giec.2025.05.004_bib126","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cgh.2022.01.058","article-title":"Effect of hormonal replacement therapy on gastroesophageal reflux disease and its complications in postmenopausal women","volume":"21","author":"Saleh","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.giec.2025.05.004_bib127","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/ijc.30588","article-title":"Menopausal hormone therapy and the risk of esophageal and gastric cancer","volume":"140","author":"Brusselaers","year":"2017","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.giec.2025.05.004_bib128","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/1055-9965.EPI-11-0834","article-title":"Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis","volume":"21","author":"Camargo","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"10.1016\/j.giec.2025.05.004_bib129","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/dote.12349","article-title":"Hormonal and reproductive factors and risk of esophageal cancer in women: a meta-analysis","volume":"29","author":"Wang","year":"2016","journal-title":"Dis Esophagus"},{"issue":"5","key":"10.1016\/j.giec.2025.05.004_bib130","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/2050640614543736","article-title":"Is hormone replacement therapy in post-menopausal women associated with a reduced risk of oesophageal cancer?","volume":"2","author":"Menon","year":"2014","journal-title":"United European Gastroenterol J"},{"issue":"4","key":"10.1016\/j.giec.2025.05.004_bib131","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.cgh.2014.08.027","article-title":"Association between circulating levels of sex steroid hormones and Barrett's esophagus in men: a case-control analysis","volume":"13","author":"Cook","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.giec.2025.05.004_bib132","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabres.2018.05.023","article-title":"Metformin in cancer","volume":"143","author":"Mallik","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"10.1016\/j.giec.2025.05.004_bib133","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cgh.2014.08.040","article-title":"Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus","volume":"13","author":"Chak","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7503","key":"10.1016\/j.giec.2025.05.004_bib134","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.giec.2025.05.004_bib135","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2337\/dc09-1380","article-title":"Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16","volume":"33","author":"Landman","year":"2010","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.giec.2025.05.004_bib136","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.gie.2015.12.036","article-title":"Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort","volume":"84","author":"Krishnamoorthi","year":"2016","journal-title":"Gastrointest Endosc"},{"issue":"2","key":"10.1016\/j.giec.2025.05.004_bib137","doi-asserted-by":"crossref","first-page":"G129","DOI":"10.1152\/ajpgi.00085.2014","article-title":"In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids","volume":"307","author":"Peng","year":"2014","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"3","key":"10.1016\/j.giec.2025.05.004_bib138","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10238-014-0301-x","article-title":"Chemoprevention of esophageal adenocarcinoma in a rat model by ursodeoxycholic acid","volume":"15","author":"Ojima","year":"2015","journal-title":"Clin Exp Med"},{"issue":"7","key":"10.1016\/j.giec.2025.05.004_bib139","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1158\/1940-6207.CAPR-15-0276","article-title":"Clinical study of ursodeoxycholic acid in Barrett's esophagus patients","volume":"9","author":"Banerjee","year":"2016","journal-title":"Cancer Prev Res"},{"issue":"2","key":"10.1016\/j.giec.2025.05.004_bib140","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1017\/S0954422410000132","article-title":"Dietary factors and the risks of oesophageal adenocarcinoma and Barrett's oesophagus","volume":"23","author":"Kubo","year":"2010","journal-title":"Nutr Res Rev"},{"issue":"4","key":"10.1016\/j.giec.2025.05.004_bib141","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1053\/j.gastro.2006.08.010","article-title":"Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis","volume":"131","author":"Larsson","year":"2006","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.giec.2025.05.004_bib142","doi-asserted-by":"crossref","first-page":"10458","DOI":"10.18632\/oncotarget.14432","article-title":"Folate intake, serum folate levels and esophageal cancer risk: an overall and dose-response meta-analysis","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.giec.2025.05.004_bib143","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/CEJ.0000000000000441","article-title":"Folate intake, serum folate, and risk of esophageal cancer: a systematic review and dose-response meta-analysis","volume":"28","author":"Ni","year":"2019","journal-title":"Eur J Cancer Prev"},{"issue":"5","key":"10.1016\/j.giec.2025.05.004_bib144","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/bjc.2014.17","article-title":"Intakes of folate, methionine, vitamin B6, and vitamin B12 with risk of esophageal and gastric cancer in a large cohort study","volume":"110","author":"Xiao","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.giec.2025.05.004_bib145","series-title":"Holitic health","author":"Jankowski","year":"2025"},{"key":"10.1016\/j.giec.2025.05.004_bib146","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3389\/fphar.2019.00852","article-title":"Omega-3 polyunsaturated fatty acids and their bioactive metabolites in gastrointestinal malignancies related to unresolved inflammation. A review","volume":"10","author":"Ir\u00fan","year":"2019","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.giec.2025.05.004_bib147","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/ajcn\/87.4.949","article-title":"Effect of n-3 polyunsaturated fatty acids on Barrett's epithelium in the human lower esophagus","volume":"87","author":"Mehta","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.giec.2025.05.004_bib148","article-title":"Relationships of omega-3 and omega-6 polyunsaturated fatty acids with esophageal diseases: a two-sample Mendelian randomization analysis","volume":"11","author":"Chen","year":"2024","journal-title":"Front Nutr"},{"issue":"4","key":"10.1016\/j.giec.2025.05.004_bib149","doi-asserted-by":"crossref","first-page":"559","DOI":"10.14309\/ajg.0000000000001680","article-title":"Diagnosis and management of Barrett's esophagus: an updated ACG guideline","volume":"117","author":"Shaheen","year":"2022","journal-title":"Am Coll Gastroenterol"},{"issue":"3","key":"10.1016\/j.giec.2025.05.004_bib150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.gie.2019.05.012","article-title":"ASGE guideline on screening and surveillance of Barrett\u2019s esophagus","volume":"90","author":"Qumseya","year":"2019","journal-title":"Gastrointest Endosc"},{"issue":"3","key":"10.1016\/j.giec.2025.05.004_bib151","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2017.05.044","article-title":"Late recurrence of Barrett's esophagus after complete eradication of intestinal metaplasia is rare: final report from ablation in intestinal metaplasia containing dysplasia trial","volume":"153","author":"Cotton","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.giec.2025.05.004_bib152","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/ajg.2016.451","article-title":"Clinical outcomes following recurrence of intestinal metaplasia after successful treatment of Barrett's esophagus with radiofrequency ablation","volume":"112","author":"Guthikonda","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.giec.2025.05.004_bib153","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/ajg.2012.413","article-title":"Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation","volume":"108","author":"Orman","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.giec.2025.05.004_bib154","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.cgh.2014.04.034","article-title":"Durability and predictors of successful radiofrequency ablation for Barrett's esophagus","volume":"12","author":"Pasricha","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.giec.2025.05.004_bib155","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/ajg.2017.13","article-title":"Recurrence of Barrett's esophagus is rare following endoscopic eradication therapy coupled with effective reflux control","volume":"112","author":"Komanduri","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.giec.2025.05.004_bib156","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1053\/j.gastro.2012.05.005","article-title":"Increased risk for persistent intestinal metaplasia in patients with Barrett's esophagus and uncontrolled reflux exposure before radiofrequency ablation","volume":"143","author":"Krishnan","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.giec.2025.05.004_bib157","doi-asserted-by":"crossref","DOI":"10.1007\/s10620-025-08908-0","article-title":"Effect of aspirin on biomarkers of Barrett's esophagus after successful eradication with radiofrequency ablation","author":"Bresalier","year":"2025","journal-title":"Dig Dis Sci"}],"container-title":["Gastrointestinal Endoscopy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052515725000492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052515725000492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T16:13:06Z","timestamp":1763741586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1052515725000492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":156,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1052515725000492"],"URL":"https:\/\/doi.org\/10.1016\/j.giec.2025.05.004","relation":{},"ISSN":["1052-5157"],"issn-type":[{"value":"1052-5157","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemoprevention in Barrett\u2019s Esophagus: An Updated Review","name":"articletitle","label":"Article Title"},{"value":"Gastrointestinal Endoscopy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.giec.2025.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}